AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00866918
Drug: Tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT02486159
Drug: Herbal plaster (Sanfujiu)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The Acupoint herbal plaster consisted of mustard seed, fumarate, asarum, angelica, cinnamon, and ginger at a ratio of 3:3:2:2:0.5:4, respectively. The treatment was prepared by dissolving the ginger in water and adding the powder to form a plaster. Mixtures were formed into cakes of approximately 1.5 × 1.5 × 0.5 cm3 and were held in position using plastic sheets.
Trial: NCT01100060
Drug: azithromycin (AZ) microsphere
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AZ microsphere (2000 mg) single dose on Day 1.
Trial: NCT01100060
Drug: azithromycin (AZ)
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AZ IR 4 x 500 mg tablets, single dose on Day 1.
Trial: NCT03551808
Drug: using of Ketorolac Tromethamine Eye Drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: using of Ketorolac Tromethamine Eye Drop one day before the surgery in each 8 hours and continue it for 4 weeks after the surgery
Trial: NCT03318783
Drug: GSK2256294
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.
Trial: NCT03318783
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered in a single dose once daily enteral for a duration of 10 days.
Trial: NCT00098306
Drug: Optimized Background Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
Trial: NCT02183116
Drug: Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03803553
Drug: FOLFIRI Protocol
RxNorm normalized name: Olay Professional Acne Protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI cycle will be two weeks (14 days) long, with FOLFIRI administered on Days 1-3. Participants will receive up to 12 two-week cycles (for a total of 24 weeks) of FOLFIRI chemotherapy.
Trial: NCT01074697
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline water
Trial: NCT01026714
Drug: flurbiprofen
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: assessment of flurbiprofen plasmatic and capillary rates
Trial: NCT01026714
Drug: flurbiprofen, rifampicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: assessment of flurbiprofen plasmatic and capillary rates
Trial: NCT01187407
Drug: LY2216684
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01187407
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01026714
Drug: flurbiprofen + fluconazole
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: assessment of flurbiprofen plasmatic and capillary rates
Trial: NCT01710917
Drug: Targinact® (oxycodon/naloxon)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01332097
Drug: BCT197
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01332097
Drug: BCT197 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsules
Trial: NCT00098306
Drug: Optimized Background Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
Trial: NCT00098306
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
Trial: NCT02191280
Drug: Antistax®, high dose
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02191280
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00098306
Drug: Optimized Background Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy \[OBT (3-6 drugs based on treatment history and resistance testing)\] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment.
Trial: NCT03269695
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC QW
Trial: NCT02715492
Drug: LMWH
RxNorm normalized name: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (Enoxheparin) 1 IU/kg per dose twice daily for 2 weeks from the 1st day of TACE
Trial: NCT01854489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The volunteers will be given Oral placebo at 20.00 for 7 days \[Phase 1 \]
Trial: NCT00084734
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT00099723
Drug: VSL#3
RxNorm normalized name: VSL#3
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02307513
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration
Trial: NCT02004106
Drug: RO6895882
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive RO6895882 at different dose levels and schedules defined in respective arms as IV infusion.
Trial: NCT03233347
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01209221
Drug: Placebo - MAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once or twice daily doses of matching placebo to RO5271983 for 14 days
Trial: NCT02726477
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administrated with placebo powder at a dosage of 1g/kg twice a day after randomisation.
Trial: NCT01209221
Drug: Placebo - SAD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of matching placebo to RO5271983 for up to 3 periods
Trial: NCT01209221
Drug: RO5271983 - MAD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Once or twice daily doses of RO5271983 for 14 days
Trial: NCT00720174
Drug: Doxorubicin Hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT01374178
Drug: LY2963016
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered subcutaneously
Trial: NCT02827942
Drug: Clarithromycin 200 mg bid
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin is antibiotics. It is involved in the standard first line regimen in Japan. Then, 200 mg of clarithromycin is dosed twice daily for 1 week.
Trial: NCT01003639
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will begin with four tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
Trial: NCT00839332
Drug: LY2603618
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01544504
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Approximately 4.65 mL of a norepinephrine solution (400 mM, 82.3 mg/mL) will be applied topically to the study drug application site prior to each radiotherapy treatment (approximately 25-28 treatments).
Trial: NCT00621816
Drug: placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: blinded placebo infusion, to be infused at same rate as open-label nitroprusside infusion
Trial: NCT02384655
Drug: Fenugreek seed meal
RxNorm normalized name: fenugreek seed meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3x3 capsules of fenugreek seeds per day for 14 days
Trial: NCT00840671
Drug: 0.9% Saline Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
Trial: NCT01324700
Drug: High severity group: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants within high severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
Trial: NCT01324700
Drug: Low severity group: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants within low severity group were stratified to receive placebo (inactive ingredient matching the active medication in appearance).
Trial: NCT03317223
Drug: CJ-12420/Clarithromycin/Amoxicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CJ-12420 or Lansoprazole +Clarithromycin/Amoxicillin will be administrated twice a day, for 7 days
Trial: NCT00130728
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
Trial: NCT02456675
Drug: INCB040093
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
Trial: NCT02496143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be supplied as Softgel capsules. The study will include up to four sequential dose cohorts. Two subjects in each cohort will be randomized to placebo and will receive 1, 2, 4 or 8 placebo capsules for Cohorts 1, 2, 3 or 4, respectively.
Trial: NCT01187810
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose depends on subject age - for CNS positive patients, will be given in combination with cytarabine and hydrocortisone on days 8, 15, and 22 during course 1. For courses 2-6, will be administered intrathecally on day 8 for CNS negative ALL and NHL. For patients who are CNS positive, it will be given in combination with cytarabine and hydrocortisone on day 8 of courses 2-6.
Trial: NCT00003216
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02402946
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03515200
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given intravenously (IV).
Trial: NCT01473472
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 tablets of placebo within 24 hours before first sexual relations, then 1 tablet of placebo every 24 hours during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of placebo approximatively 24 hours later
Trial: NCT02483598
Drug: Buspirone and Grapefruit Juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice will be given before and during buspirone administration to inhibit intestinal CYP3A4.
Trial: NCT02970305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, taken as two tablets, once daily by mouth
Trial: NCT00450398
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient prior to arterial reperfusion of the liver.
Trial: NCT00099203
Drug: ibandronate [Bondronat]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6mg iv on days 1-3, and every 3-4 weeks
Trial: NCT00099203
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4mg iv on day 1 and every 3-4 weeks
Trial: NCT03295266
Drug: MK-3866
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single IV infusion of MK-3866 150 mg administered over 30 minutes at Hour 0 on Day 1 of treatment period.
Trial: NCT01665599
Drug: Testosterone gel (FE 999303)
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03984838
Drug: JULUCA (Dolutegravir and Rilpivirine) 50mg/25mg FDC tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JULUCA tablets will be administered orally once daily with a meal. It will be available as a fixed dose combination of Dolutegravir 50mg and Rilpivirine 25mg.
Trial: NCT04121039
Drug: POF
RxNorm normalized name: Ta-Poff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
Trial: NCT03734991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT04182880
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered
Trial: NCT04263298
Drug: Capecitabine Oral Product
RxNorm normalized name: capecitabine Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine 2000mg/m2 twice daily x 14 days followed by 7 days off
Trial: NCT02696902
Drug: MEDI3902
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single IV dose of MEDI3902 500 mg and 1500 mg in MEDI3902 500 mg arm and MEDI3902 1500 mg arm, respectively.
Trial: NCT03421496
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching oral solution
Trial: NCT02716038
Drug: MPDL3280A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MPDL3280A is a human, Fc optimized, monoclonal antibody directed against the protein ligand programmed cell death-1 ligand 1 (PD-L1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. MPDL3280A 1200 mg will be administered as a 60 minute IV infusion on first administration, then over 30 minutes subsequently if tolerated.
Trial: NCT04360434
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation buffer of NI006, matching volume of NI006 doses will be administered intravenously
Trial: NCT00691678
Drug: Glucosamine
RxNorm normalized name: Glucosamine
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500mg glucosamine TID for twenty-four weeks
Trial: NCT01218425
Drug: Levodopa/carbidopa 125 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral dose, 100 mg levodopa, 25 mg carbidopa in one capsule
Trial: NCT02872519
Drug: (S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG)
RxNorm normalized name: 18F-FSPG
DrugBank: Florilglutamic acid F-18 (DB15041)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given by IV
Trial: NCT01684111
Drug: BIBF 1120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 x 150 mg capsules, oral, daily (Start dose)
Trial: NCT02485327
Drug: Technosphere Insulin SAR439065 Afrezza®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: dry powder~Route of administration: oral inhalation
Trial: NCT00033943
Drug: deligoparin
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02807961
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo comparator
Trial: NCT01028755
Drug: BAY79-4620
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY79-4620 will be administered as 1 hour IV infusion. Dose escalation will be dependent on any dose limiting toxicities
Trial: NCT02916706
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02826798
Drug: VBI-1501A 0.5 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VBI-1501A: 0.5 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
Trial: NCT02826798
Drug: VBI-1501A 1.0 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VBI-1501A: 1.0 μg with alum with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
Trial: NCT02826798
Drug: VBI-1501A 2.0 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VBI-1501A: 2.0 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
Trial: NCT02826798
Drug: VBI-1501 1.0 μg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VBI-1501: 1.0 μg without alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
Trial: NCT02826798
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: buffer/sucrose used for VBI-1501 suspension- administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168.
Trial: NCT01268098
Drug: NPSP558
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will inject NPSP558 25 or 50 µg SC QD into alternating thighs in the morning via a multidose injection pen device.
Trial: NCT00034853
Drug: meloxicam oral suspension
RxNorm normalized name: Meloxicam Oral Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03888222
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fifteen (15) patients in group 1 will receive the matching placebo(sugar pill) one (1) tablet orally once daily for 3 months (90 days) .
Trial: NCT03921242
Drug: Sulfonylurea
RxNorm normalized name: Sulfonylurea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newly initiated and regular sulfonylurea dosage as prescribed by each patient's medical care provider
Trial: NCT03921242
Drug: GLP1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Newly initiated and regular GLP1 receptor agonist dosage as prescribed by each patient's medical care provider
Trial: NCT02561078
Drug: Human regular U-500 insulin (CSII)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT02561078
Drug: Human regular U-500 insulin (MDI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT04333732
Drug: MR or M-M-R II ® vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Education and surveillance plus MR or M-M-R II ® vaccine
Trial: NCT04333732
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection
Trial: NCT00148252
Drug: Mycophenolate mofetil withdrawal
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03376698
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral administration of Placebo once daily for 12 weeks
Trial: NCT01828359
Drug: Amosartan® tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different combination of anti-hypertension drug
Trial: NCT01828359
Drug: Cozaar® plus pro tab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparison of different combination of anti-hypertension drug
Trial: NCT00119990
Drug: Physioneal (dialysate) 1.36% and 2.27%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 liter of Physioneal of 1.36% or 3.86% are given with one fill for 4 hours one two different days.
Trial: NCT03418493
Drug: LY3316531 - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT03418493
Drug: Placebo - IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT02418845
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00721812
Drug: GSK1399686
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and tolerability dose escalation in normal human volunteers
Trial: NCT00874432
Drug: angiotensin converting enzyme inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day
Trial: NCT00790114
Drug: AZD7325
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, day 1-12
Trial: NCT00790114
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single dose, twice during treatment
Trial: NCT01809041
Drug: remifentanil
RxNorm normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03417037
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based doublet chemotherapy
Trial: NCT03460847
Drug: Steroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with active colitis ulcerosa who need steroids because of their disease course. 1mg/kg bodyweight for one week, followed by a tapping periode.